Delphine BADINAND
MD
-
Onco-radiotherapist at the Timone Hospital
APHM
MI is a diamond of the new Metropolis, offering a unique opportunity to drive science forward and provide more effective therapeutic options for our cancer patients.
Cancerology is booming and immunotherapy represents the most promising approach. At the APHM we have been at the forefront of these therapeutic advances and as a radiotherapist, I’m developing new strategies combining radiotherapy and immunotherapy to reach the « abscopal effect ». MI is a diamond of the new Metropolis, offering a unique opportunity to drive science forward and provide more effective therapeutic options for our cancer patients.
#cliniqueHave a look on our testimonies
MI both accelerates research and development in immuno-oncology and offers cancer patients more options in terms of diagnostics and treatments, as well as more innovative clinical trials.
Fabrice BARLESI
Université Paris-Saclay, Gustave Roussy, The Pioneer Project
Marseille Immunopole should allow us now to accelerate the development of therapeutic antibodies, the new drugs that are changing the course of cancer treatment.
Jean-Paul BORG
AMU, IPC, CRCM
Understanding its mechanisms of action and proposing new diagnostic and therapeutic solutions is the ambitious project that we set with my team.
Marcel BLOT-CHABAUD
VRCM
Diagnostic in immuno-oncology is an innovative field combining the latest discoveries in immunology and new imaging technologies, such as digital pathology.
Fabienne HERMITTE
Veracyte
your commitment to MI